Since the comprehensive recommendations for the management of acute promyelocytic
leukemia (APL) reported in 2009, several studies have provided important insights …

Arsenic trioxide and all-trans retinoic acid have become the frontline treatments for patients
with acute promyelocytic leukemia (APL). Despite the long wait for an oral arsenic drug, a …

A common key regulator of oncogenic signaling pathways in multiple tumor types is the
unique isomerase Pin1. However, available Pin1 inhibitors lack the required specificity and …

Differentiation syndrome (DS), formerly known as retinoic acid syndrome, is a relatively
common and potentially severe complication seen in patients with acute promyelocytic …

BACKGROUND Race‐based survival in children and adolescents with hematologic
malignancies has been a national challenge for decades. Large‐scale investigations of age …

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML)
with a unique morphological appearance, associated coagulopathy and canonical balanced …

Acute promyelocytic leukemia (APL) is a hyper-acute illness and presents with profound
cytopenias in most patients and disseminated intravascular coagulation (DIC). Excellent …

Arsenic Trioxide is an old drug that has recently re-introduced into new medicine. It is very
potent against a specific type of leukemic cells harboring translocation between …

Despite the improved therapeutic advances in the management of acute promyelocytic
leukemia (APL), a significant early mortality during induction, also referred to as early death …

Acute myeloid leukemia (AML) is a heterogeneous disease in its clinical presentation,
response to therapy, and overall prognosis. For decades, pretreatment karyotype evaluation …